PharmaCyte Biotech sets 1-for-19 reverse stock split for November 12
PMCB•PharmaCyte Biotech will implement a 1-for-19 reverse stock split effective November 12, 2026, to restore compliance with Nasdaq’s minimum bid price requirement. Split-adjusted trading will begin November 13, reducing outstanding common shares from approximately 10,755,649 to 566,087.
